Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections | Frontline Gastroenterology

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

CME/CPD

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Letter

Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections

Online download statistics by month:

Online download statistics by month: March 2021 to March 2024

	Abstract	Full	Pdf
Mar 2021	1076	25	20
Apr 2021	105	7	6
May 2021	100	7	4
Jun 2021	5	0	0
Jul 2021	6	0	2
Aug 2021	3	0	0
Sep 2021	1	1	1
Oct 2021	46	2	1
Nov 2021	48	5	4
Dec 2021	538	10	7
Jan 2022	330	19	12
Feb 2022	180	14	7
Mar 2022	108	7	4
Apr 2022	110	8	5
May 2022	83	2	0
Jun 2022	70	4	0
Jul 2022	76	5	3
Aug 2022	74	0	0
Sep 2022	85	1	0
Oct 2022	79	4	3
Nov 2022	37	0	0
Dec 2022	84	1	1
Jan 2023	28	2	1
Feb 2023	98	1	0
Mar 2023	36	4	0
Apr 2023	23	3	2
May 2023	24	1	0
Jun 2023	19	0	0
Jul 2023	27	0	1
Aug 2023	21	0	0
Sep 2023	13	0	0
Oct 2023	16	0	0
Nov 2023	27	2	1
Dec 2023	29	0	0
Jan 2024	52	1	1
Feb 2024	38	1	0
Mar 2024	43	5	0
Total	3738	142	86